Department of Neurology, Yale School of Medicine, New Haven, CT 06520, USA.
Toxins (Basel). 2013 May 21;5(5):1010-31. doi: 10.3390/toxins5051010.
Sialorrhea or excessive drooling is a major issue in children with cerebral palsy and adults with neurodegenerative disorders. In this review, we describe the clinical features, anatomy and physiology of sialorrhea, as well as a review of the world literature on medical treatment using Yale University's search engine; including but not limited to Medline and Erasmus. Level of drug efficacy is defined according to the guidelines of American Academy of Neurology. Current medical management is unsatisfactory. Topical agents (scopolamine and tropicamide) and oral agents (glyccopyrolate) combined render a level B evidence (probably effective); however, this treatment is associated with troublesome side effects. Double-blind and placebo-controlled studies of botulinum toxin (BoNT) provide a level A evidence for type B (two class I studies; effective and established) and both overall and individual B level of evidence for OnabotulinumtoxinA (A/Ona) and AbobotulinumtoxinA (A/Abo); these are probably effective. For IncobotulinumtoxinA (A/Inco), the level of evidence is U (insufficient) due to lack of blinded studies. Side effects are uncommon; transient and comparable between the two types of toxin. A clinical note at the end of this review comments on fine clinical points. Administration of BoNTs into salivary glands is currently the most effective way of treating sialorrhea.
流涎症或过度流涎是脑瘫儿童和神经退行性疾病成人的主要问题。在这篇综述中,我们描述了流涎症的临床特征、解剖和生理学,以及对耶鲁大学搜索引擎上的医学治疗世界文献的综述;包括但不限于 Medline 和 Erasmus。药物疗效水平根据美国神经病学学会的指南定义。目前的医学治疗并不令人满意。局部制剂(东莨菪碱和托吡卡胺)和口服制剂(格隆溴铵)联合使用具有 B 级证据(可能有效);然而,这种治疗与麻烦的副作用有关。肉毒杆菌毒素(BoNT)的双盲和安慰剂对照研究为 B 型(两项 I 级研究;有效且确立)提供了 A 级证据,对 A/Ona 和 A/Abo 提供了整体和个体 B 级证据;这些可能是有效的。对于 IncobotulinumtoxinA(A/Inco),由于缺乏盲法研究,证据水平为 U(不足)。副作用不常见;在两种类型的毒素之间是短暂且可比的。本综述末尾的临床注释评论了细微的临床要点。将 BoNTs 注入唾液腺是目前治疗流涎症最有效的方法。